Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Alibaba Group (BABA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Alibaba Group — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.78 (market cap $4.49B), while Alibaba Group trades at $109.21 (market cap $234.34B). The key difference: Alibaba Group is far larger — about 52.2× ACADIA Pharmaceuticals Inc.'s market cap, and Alibaba Group pays a 1.07% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | BABA | |
|---|---|---|
Market Cap | $4.49B | $234.34B |
Sector | Health | Consumer Cyclical |
52-Week High | $28.06 | $189.34 |
52-Week Low | $20.06 | $94.83 |
Enterprise Value | $3.69B | $229.16B |
Volume | — | 18,069,938 |
Dividend Yield | — | 1.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Alibaba (BABA) trades at $98.14, up 2.08% today, but remains in a bearish technical trend with recent earnings misses. The company reported strong revenue growth to $996.35B in 2025 and a net income margin of 13.05%, yet faces headwinds from regulatory investigations and a $600M DOJ settlement. Analyst consensus is overwhelmingly bullish with an $195 price target, highlighting a significant discount to intrinsic value despite near-term challenges.
The stock presents a contrarian opportunity with attractive valuations (P/E 15.13, P/S 1.56) amid pessimism. Key risks include ongoing legal probes, AI competition, and macroeconomic pressures. Upside depends on earnings recovery and resolution of regulatory overhangs, making it a high-risk, high-reward play for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Alibaba Group
Alibaba Group Holding Limited operates as a holding company. The Company provides internet infrastructure, electronic commerce, online financial, and internet content services through its subsidiaries. Alibaba Group Holding offers its products and services worldwide.
Read more on BABA →
